Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population

Thoracic Oncology Laboratory, Department ofCardiothoracic Surgery, NYU School of Medicine, New York, NY, USA Division of Hematology and Oncology, NYU School of Medicine, New York, NY, USA.
Cancer biomarkers: section A of Disease markers (Impact Factor: 1.72). 01/2012; 12(4):177-84. DOI: 10.3233/CBM-130306
Source: PubMed


As CT screening is integrated into non-small cell lung cancer (NSCLC) care, additional parameters are needed to help distinguish cancers from benign nodules. Osteopontin (OPN), a secreted phosphoprotein, has elevated plasma levels in NSCLC. We hypothesize that changes in plasma OPN over time (i.e., OPN velocity [OPNV]) can differentiate NSCLC patients from those without cancer in a CT screening population.
A nested case-control study was conducted within a NSCLC CT screening trial. Incident cancers with serial plasma were matched to controls. OPN was measured by ELISA. Demographic, OPN, and OPNV were compared between cancers and controls using Wilcoxon Signed Rank tests.
Ten incident cancers were identified. The pack years distributions were similar, but cancers were older (median of the paired difference: 5.35 years; p=0.002) and their surveillance intervals were shorter (median of the paired difference: -2 months; p=0. 03) than matched controls. Baseline OPN was similar (median of the paired difference: -5.15 ng/ml, p=0.50), but OPNV in the cancers was significantly greater than that of matched controls, (median of the paired difference: 1.06 ng/ml/month, p=0.01). Accuracy rate for prediction of disease status based on OPNV (adjusted for age and surveillance) was 83%.
These are early evidence for utility of monitoring plasma OPN during CT screening to assist in identification of NSCLCs.

7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the association of Osteopontin (OPN) expression in tumor tissue with clinicopathological features of non-small cell lung carcinoma (NSCLC) patients. Publications assessing the clinicopathological characteristics and prognostic significance of OPN in expression NSCLC were identified up to March 2014. A meta-analysis of eligible studies was performed using standard statistical methods to clarify the association between OPN expression and these clinical parameters. A total of eleven studies met the inclusion criteria, and included 1536 cases of NSCLC tumor tissue and 340 cases of normal lung tissue. The OPN expression rate in NSCLC tissue was higher than normal tissue [Odds ratio (OR) 6.427; 95 % confidence interval (CI) 4.689-8.808; P = 0.000]. Simultaneously, we also found that OPN expression was positively associated with stage (OR 0.332; 95 % CI 0.250-0.440; P = 0.000), lymph node metastasis (OR 3.094; 95 % CI 2.295-4.172; P = 0.000), tumor size (tumor size <3 cm vs. ≥3 cm; OR 0.484; 95 % CI 0.303-0.773; P = 0.002) and pathology (OR 0.611; 95 % CI 0.466-0.800; P = 0.000). It was unrelated that OPN expression in NSCLC tissue with and degree of differentiation and other clinical features (P > 0.05). Experimental findings indicate that, OPN plays a crucial role in the development of NSCLC.
    Journal of molecular histology 05/2014; 45(5). DOI:10.1007/s10735-014-9574-3 · 1.82 Impact Factor
  • Source

    Respiratory Investigation 09/2014; 52(5). DOI:10.1016/j.resinv.2014.06.002